ID

16696

Descripción

Sponsor: OSI Pharmaceuticals Information provided by (Responsible Party): Astellas Pharma Inc (OSI Pharmaceuticals) A multicenter, randomized, double-blind, placebo-controlled, phase 3 study of single-agent Tarceva® (erlotinib) following complete tumor resection with or without adjuvant chemotherapy in patients with stage IB-IIIA non-small cell lung carcinoma who have EGFR-positive tumors. See https://clinicaltrials.gov/ct2/show/NCT00373425 Part of Study: Adverse Events

Link

https://clinicaltrials.gov/ct2/show/NCT00373425

Palabras clave

Versiones (1)
  1. 1/8/16 1/8/16 -
Subido en

1 de agosto de 2016

DOI

Para solicitar uno, por favor iniciar sesión.

Licencia

Creative Commons BY 4.0
Comentarios del modelo :

Puede comentar sobre el modelo de datos aquí. A través de las burbujas de diálogo en los grupos de elementos y elementos, puede agregar comentarios específicos.

Volver a los comentarios del modelo
Comentarios de grupo de elementos para :

Comentarios del elemento para :

Para descargar modelos de datos, debe haber iniciado sesión. Por favor iniciar sesión o Registrate gratis.

Adverse Events, Tarceva in NSCLC patients who have EGFR-positive tumors DRKS00001485 NCT00373425

Inglés

Adverse Events, Tarceva in NSCLC patients who have EGFR-positive tumors NCT00373425

1 formularios  
Adverse Events
Descripción

Adverse Events

Did any Adverse Events occur?
Descripción

Adverse Events

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0877248
Long-Term Follow-Up Adverse Events
Descripción

Long-Term Follow-Up Adverse Events

Sign/Symptom or Adverse Event
Descripción

Record ALL Baseline Signs and Symptoms that occur within 24 hours prior to First Dosing. ALL Adverse Events, including Serious Adverse Events should be recorded. In addition, ALL Serious Adverse Events must be recorded on the Serious Adverse Event Report Form.

Tipo de datos

text

Alias
UMLS CUI [1]
C0877248
Severity (CTC Grade)
Descripción

Grade severity (1,2,3,4,5) using NCI Common Terminology Criteria for Adverse Events (CTCAE) Version 3.0. A change in CTC grade should be recorded as a separate event.

Tipo de datos

integer

Alias
UMLS CUI [1]
C1710066
Start Date: pretreatment
Descripción

Adverse Event Start Date

Tipo de datos

boolean

Alias
UMLS CUI [1]
C2697888
Start Date
Descripción

If not pretreatment, please specify start date

Tipo de datos

date

Alias
UMLS CUI [1]
C2697888
Stop Date: continuing
Descripción

Adverse Event End Date

Tipo de datos

boolean

Alias
UMLS CUI [1]
C2697886
Stop Date
Descripción

If not continuing, please specify stop date

Tipo de datos

date

Alias
UMLS CUI [1]
C2697886
Serious
Descripción

If event is serious, complete the SERIOUS ADVERSE EVENT FORM and fax to the appropriate number on the CRF General lnstructions page.

Tipo de datos

boolean

Alias
UMLS CUI [1]
C1710056
Related to study treatment
Descripción

A change in relationship should be recorded as a separate event.

Tipo de datos

boolean

Alias
UMLS CUI [1]
C1510821
Action taken
Descripción

If event caused drug discontinuation, complete the Withdrawal From Study Due To Nonserious Adverse Event Form and fax to the appropriate number on the CRF General lnstructions page.

Tipo de datos

integer

Alias
UMLS CUI [1]
C2826626
Volver a la parte superior de la página

Similar models

Adverse Events, Tarceva in NSCLC patients who have EGFR-positive tumors NCT00373425

1 formularios
Name
Tipo
Description | Question | Decode (Coded Value)
Tipo de datos
Alias
Item Group
Adverse Events
Adverse Events
Item
Did any Adverse Events occur?
boolean
C0877248 (UMLS CUI [1])
Item Group
Long-Term Follow-Up Adverse Events
Adverse Events
Item
Sign/Symptom or Adverse Event
text
C0877248 (UMLS CUI [1])
Item
Severity (CTC Grade)
integer
C1710066 (UMLS CUI [1])
Adverse Event Severity
Code List
Severity (CTC Grade)
CL Item
1 (1)
CL Item
2 (2)
CL Item
3 (3)
CL Item
4 (4)
CL Item
5 (5)
Adverse Event Start Date
Item
Start Date: pretreatment
boolean
C2697888 (UMLS CUI [1])
Adverse Event Start Date
Item
Start Date
date
C2697888 (UMLS CUI [1])
Adverse Event End Date
Item
Stop Date: continuing
boolean
C2697886 (UMLS CUI [1])
Adverse Event End Date
Item
Stop Date
date
C2697886 (UMLS CUI [1])
Seriousness of Adverse Event
Item
Serious
boolean
C1710056 (UMLS CUI [1])
Relation to study treatment
Item
Related to study treatment
boolean
C1510821 (UMLS CUI [1])
Item
Action taken
integer
C2826626 (UMLS CUI [1])
Action Taken
Code List
Action taken
CL Item
None (1)
CL Item
Dose Reduced (2)
CL Item
Dose Temporarily Withheld (3)
CL Item
Dose Temporarily Withheld and Reduced (4)
CL Item
Drug Discontinued (5)
Volver a la parte superior de la página 

Contacto

Utilice este formulario para comentarios, preguntas y sugerencias.

Los campos marcados con * son obligatorios.

Ayuda

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial